Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Neurocrine Biosciences (NBIX) over the last 13 years, with Q4 2025 value amounting to $2.6 million.

  • Neurocrine Biosciences' Treasury Shares rose 833.33% to $2.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.6 million, marking a year-over-year increase of 833.33%. This contributed to the annual value of $2.6 million for FY2025, which is 833.33% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Treasury Shares stood at $2.6 million, which was up 833.33% from $1.5 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Treasury Shares ranged from a high of $2.6 million in Q4 2025 and a low of $1.4 million during Q1 2025
  • Its 3-year average for Treasury Shares is $2.0 million, with a median of $2.0 million in 2023.
  • As far as peak fluctuations go, Neurocrine Biosciences' Treasury Shares changed by 0.0% in 2024, and later soared by 833.33% in 2025.
  • Neurocrine Biosciences' Treasury Shares (Quarter) stood at $2.4 million in 2023, then changed by 0.0% to $2.4 million in 2024, then increased by 8.33% to $2.6 million in 2025.
  • Its Treasury Shares was $2.6 million in Q4 2025, compared to $1.5 million in Q3 2025 and $1.5 million in Q2 2025.